VivoSeq
Psychiatry

Bipolar Depression

1

Pipeline Programs↗

13

Active Trials↗

5

Companies Involved↗

Bipolar Depression is an early-stage landscape with 1 program across 5 companies. The most active players are Eli Lilly, AstraZeneca, Pfizer. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

19/100

Mech. Concentration

100/100

Completion Rate

76/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 3AstraZeneca logo

AstraZeneca

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalK

Korea Otsuka Pharmaceutical Co., Ltd.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Lumateperone

Intra-Cellular Therapies, Inc.

Analysis

Trial Status

108

clinical trials

Completed65 · 60%
Terminated14 · 13%
Recruiting9 · 8%
Unknown status8 · 7%
Withdrawn6 · 6%
Not yet recruiting3 · 3%
Other3 · 3%

Clinical Trials

Trial Activity

108 trials

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
Recruiting·UUniversity Health Network, Toronto·Phase 1·NCT06506019·30 enrolled
Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)
Recruiting·—·Phase 4·NCT05913947·122 enrolled
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Recruiting·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 3·NCT03423680·390 enrolled
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
Recruiting·MMassachusetts General Hospital·Phase 2·NCT02481245·30 enrolled
Cannabidiol for Bipolar Depression (CBD-BD)
Recruiting·UUniversity of British Columbia·Phase 3·NCT05867849·360 enrolled
HD-tDCS for Adolescent Bipolar Depression Targeting S1
Recruiting·JJiangsu Province Nanjing Brain Hospital·N/A·NCT07246044·100 enrolled
OSU6162 in Bipolar Depression (OBID)
Recruiting·GGöteborg University·Phase 2·NCT05296356·22 enrolled
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Recruiting·LLaureate Institute for Brain Research, Inc.·Phase 1/2·NCT06088732·20 enrolled
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lumateperone for the Treatment of Major Depressive Episodes (MDEs) Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) in Pediatric Patients Aged 10 to 17 Years
Recruiting·IIntra-Cellular Therapies, Inc.·Phase 3·NCT06372964·384 enrolled
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
Active, not recruiting·MMassachusetts General Hospital·Phase 4·NCT06433635·2,726 enrolled
Dopamine D3 Receptor Occupancy in Bipolar Depression
Not yet recruiting·NNew York State Psychiatric Institute·Phase 4·NCT05060549·8 enrolled
Empagliflozin Adjunctive Therapy in Bipolar Depression
Not yet recruiting·UUniversity of Sao Paulo·N/A·NCT07472920·20 enrolled
The Effects of Lumateperone on Obesity and Physiologic Aging and Their Correlation With Antidepressant Response in Bipolar Depression
Not yet recruiting·MMassachusetts General Hospital·Approved·NCT07699445·25 enrolled
Clinical Trial of Mifepristone for Bipolar Depression
Completed·National Institute of Mental Health (NIMH)·Phase 2·NCT00043654·110 enrolled
Liothyronine (T3) for Bipolar Depression
Completed·NNorthwell Health·Phase 3·NCT00790738·11 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)